TLDR ISRG hit a 52-week low of $427.79, down nearly 6% on the day The stock is down over 20% year-to-date and 16% over the past year Large institutional investorsTLDR ISRG hit a 52-week low of $427.79, down nearly 6% on the day The stock is down over 20% year-to-date and 16% over the past year Large institutional investors

Intuitive Surgical (ISRG) Stock Hits 52-Week Low — What’s Behind the Sell-Off?

2026/05/12 00:28
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 [email protected]으로 연락주시기 바랍니다

TLDR

  • ISRG hit a 52-week low of $427.79, down nearly 6% on the day
  • The stock is down over 20% year-to-date and 16% over the past year
  • Large institutional investors have been cutting their stakes in the company
  • FDA safety alerts and product recalls tied to the da Vinci surgical system are adding pressure
  • Despite the drop, 15 analysts recently revised earnings estimates upward and multiple firms maintain Outperform ratings

Intuitive Surgical (ISRG) stock fell to a 52-week low of $427.79 on Monday, closing down roughly 6% as institutional selling and product safety concerns weighed on the stock.


ISRG Stock Card
Intuitive Surgical, Inc., ISRG

The drop brings ISRG’s year-to-date loss to over 20%, a tough stretch for a company that reported strong Q1 2026 results just weeks ago.

In Q1, Intuitive posted a 23% jump in sales to $2.77 billion and a 38% rise in earnings per share to $2.50. Both figures beat analyst estimates — revenue by 6% and EPS by 19%.

So why is the stock falling? Analysts point to a few company-specific factors rather than any broad market sell-off.

Large institutional investors have been trimming their positions, raising questions about whether ISRG’s valuation still holds up after a strong run. That selling pressure has unsettled traders who were already watching the stock closely.

On top of that, ongoing concerns around FDA safety alerts and product recalls linked to the da Vinci surgical system have added fuel to the decline. These aren’t new issues, but they continue to hang over sentiment.

Analysts Stay Bullish Despite the Slide

Despite the sell-off, Wall Street hasn’t turned negative on the stock. Bernstein SocGen Group reiterated an Outperform rating with a price target of $750. RBC Capital also kept its Outperform rating, with a $650 target.

Piper Sandler and Barclays both maintained Overweight ratings. Piper Sandler trimmed its target to $580, while Barclays held at $651. Both firms pointed to solid procedure volumes and system placements as positives from the Q1 print.

Fifteen analysts have recently revised their earnings estimates upward, and InvestingPro data suggests the stock may be undervalued relative to its Fair Value at current levels.

ISRG’s current market cap sits at around $159.4 billion. Average daily trading volume runs at roughly 1.9 million shares.

Technical Picture

The technical sentiment signal on ISRG is currently rated Hold. Revenue growth over the last twelve months came in at 21.43% as of Q1 2026, which remains a solid fundamental backdrop even as the stock sells off.

The stock’s 52-week high stands in sharp contrast to where it trades today, with the gap reflecting just how much ground ISRG has given back this year.

As of Monday’s close, ISRG was trading at $423.22, down $26.84 on the day.

The post Intuitive Surgical (ISRG) Stock Hits 52-Week Low — What’s Behind the Sell-Off? appeared first on CoinCentral.

SPACEX(PRE) Launchpad Is Live

SPACEX(PRE) Launchpad Is LiveSPACEX(PRE) Launchpad Is Live

Start with $100 to share 6,000 SPACEX(PRE)

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, [email protected]으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

No Chart Skills? Still Profit

No Chart Skills? Still ProfitNo Chart Skills? Still Profit

Copy top traders in 3s with auto trading!